Skip to main content
. 2023 Jun 28;11(6):e006890. doi: 10.1136/jitc-2023-006890

Figure 2.

Figure 2

PRMT5 suppresses the ferroptosis of TNBC cells by downregulating HMOX1. (A,B) After 6 hours of treatment with 3 μM RSL3, the expression of HMOX1 in differentially treated MDA-MB-231 and HCC1937 cells at the mRNA (B) and protein (C) levels was examined by RT-qPCR (B) and western blotting (C), respectively. (D–F) HCC1937 and MDA-MB-231 cells overexpressing or not overexpressing HMOX1 were transfected with PRMT5 and then treated with 1 μM RSL3. After 12-hour and 24-hour treatments, MTT and MDA assays were performed to determine cell viability and intracellular MDA, respectively. Intracellular ferrous content was assessed by an Iron Assay Kit after 6 hours. Average of three experiments. **p<0.01. PRMT5, protein arginine methyltransferase 5; TNBC, triple-negative breast cancer; DMSO, dimethyl sulfoxide; JNJ, PRMT5 inhibitor, Onametostat (JNJ-64619178).